Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects.

Okour M, Puri A, Chen G, Port K, Berni A, Khindri S, Schneider I, Tenero D.

Clin Ther. 2019 Jun;41(6):1110-1127. doi: 10.1016/j.clinthera.2019.04.007. Epub 2019 May 4.

PMID:
31060740
2.

Use of Both Qualitative and Quantitative Methods to Estimate Meaningful Change Thresholds for Key Endpoints in Pediatric Asthma Trials.

Arbuckle R, Staunton H, Sully K, Tomkins S, Khindri S, Svedsater H, Nelsen L.

Value Health. 2019 Mar;22(3):340-347. doi: 10.1016/j.jval.2018.09.2845. Epub 2018 Dec 6.

PMID:
30832972
3.

A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.

Khindri S, Cahn A, Begg M, Montembault M, Leemereise C, Cui Y, Hogg A, Wajdner H, Yang S, Robertson J, Hamblin JN, Ludwig-Sengpiel A, Kornmann O, Hessel EM.

J Pharmacol Exp Ther. 2018 Dec;367(3):405-413. doi: 10.1124/jpet.118.249516. Epub 2018 Sep 14.

PMID:
30217958
4.

Corrigendum to "Knemometry Assessment of Short-term Growth in Children with Asthma Receiving Fluticasone Furoate for 2 Weeks: A Randomized, Placebo-controlled, Cross-over Trial" Clin Ther 2017;39:1191-1199.

Wolthers OD, Stone S, Bareille P, Tomkins S, Khindri S.

Clin Ther. 2017 Sep;39(9):1904. doi: 10.1016/j.clinthera.2017.08.007. Epub 2017 Aug 24. No abstract available.

5.

Knemometry Assessment of Short-term Growth in Children With Asthma Receiving Fluticasone Furoate for 2 Weeks: A Randomized, Placebo-controlled, Crossover Trial.

Wolthers OD, Stone S, Bareille P, Tomkins S, Khindri S.

Clin Ther. 2017 Jun;39(6):1191-1199. doi: 10.1016/j.clinthera.2017.04.011. Epub 2017 May 22. Erratum in: Clin Ther. 2017 Sep;39(9):1904.

6.

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD.

Rheault T, Khindri S, Vahdati-Bolouri M, Church A, Fahy WA.

ERJ Open Res. 2016 Apr 27;2(2). pii: 00101-2015. eCollection 2016 Apr.

7.

Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.

Vaidya SS, Khindri S, Maahs S, Machineni S, Hara H, Juan A, Kaiser G.

Clin Pharmacol Drug Dev. 2016 Jul;5(4):285-95. doi: 10.1002/cpdd.245. Epub 2016 Jan 22.

PMID:
27310329
8.

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.

Feldman G, Maltais F, Khindri S, Vahdati-Bolouri M, Church A, Fahy WA, Trivedi R.

Int J Chron Obstruct Pulmon Dis. 2016 Apr 7;11:719-30. doi: 10.2147/COPD.S102494. eCollection 2016.

9.

Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.

Vaidya SS, Khindri S, Calder N, Machineni S, Hara H, Majumdar T, Febbraro S, Fuhr R, Woessner R.

Pulm Pharmacol Ther. 2016 Apr;37:30-6. doi: 10.1016/j.pupt.2016.01.004. Epub 2016 Feb 1.

PMID:
26845343
10.

Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.

Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, Cheng Y, Khindri S, Kovarik JM, Ma S, McCormack FX, Henske EP.

Eur Respir J. 2015 Sep;46(3):783-94. doi: 10.1183/09031936.00210714. Epub 2015 Jun 25.

11.

Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.

Shimada S, Vaidya S, Khindri S, Tashiro N, Cheng Y, Hara H, Majumdar T, Woessner R, Furihata K, Kobayashi K.

Int J Clin Pharmacol Ther. 2015 May;53(5):398-407. doi: 10.5414/CP202239.

PMID:
25740265
12.

In Vitro-In Vivo Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler®.

Weers JG, Clark AR, Rao N, Ung K, Haynes A, Khindri SK, Perry SA, Machineni S, Colthorpe P.

J Aerosol Med Pulm Drug Deliv. 2015 Aug;28(4):268-80. doi: 10.1089/jamp.2014.1178. Epub 2014 Dec 17.

PMID:
25517988
13.

Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers.

Jiang J, Li L, Yin H, Woessner R, Emotte C, Li R, Khindri S, Pei H.

Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):203-8. doi: 10.1007/s13318-014-0197-6. Epub 2014 Apr 6.

14.

Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.

Beeh KM, Wagner F, Khindri S, Drollmann AF.

COPD. 2011 Oct;8(5):340-5. doi: 10.3109/15412555.2011.594464. Epub 2011 Jul 27.

PMID:
21793716
15.

Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study.

Khindri S, Sabo R, Harris S, Woessner R, Jennings S, Drollmann AF.

BMC Pulm Med. 2011 May 26;11:31. doi: 10.1186/1471-2466-11-31.

Supplemental Content

Loading ...
Support Center